Using synbiotics to prevent mucositis in colorectal cancer patients undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effect of synbiotic supplementation on preventing mucositis and diarrhea in patients with colorectal cancer receiving chemotherapy. It aims to determine whether administering synbiotics before chemotherapy can mitigate gastrointestinal damage caused by treatment, which often leads to severe complications. The study will include patients who are newly diagnosed with colorectal cancer and are eligible for chemotherapy with capecitabine. Participants will be monitored for symptoms of mucositis and diarrhea throughout their treatment regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Colorectal tumor in the first oncological treatment
* Age over 18 years old
* Both sexes
* Eligible for protocol with capecitabine alone or associated with oxaliplatin
* Patients WITHOUT colostomy or WITH colostomy in the transverse/descending/sigmoid region
* Patient undergoing Radiotherapy treatment associated with Chemotherapy
* Patients residing in Belo Horizonte and the metropolitan region
* Patients who Accept and sign the Informed Consent Form (TCLE)

Exclusion Criteria:

* Diagnosis of gastrointestinal carcinoid and stromal tumor (GIST)
* Patients with Ileostomy
* Patients with colostomy in the ascending region of the colon
* Inflammatory bowel diseases: Crohn's and Colitis
* Use of antibiotics and antifungals in the last 15 days
* Use of prebiotic/probiotic and/or synbiotic in the last 15 days
* Use of antidiarrheal medication in the last 15 days
* Presence of fever and mucus discharge
* Pregnant or breastfeeding women
* Patients who refuse to participate in the study.

Where it's running

• Escola de Enfermagem - UFMG
  Belo Horizonte, Minas Gerais, Brazil Recruiting

Study contacts

• Principal investigator: Simone de Vasconcelos Generoso — Escola de Enfermagem - UFMG
• Study coordinator: Simone de Vasconcelos Generoso
• Email: simonenutufmg@gmail.com
• Phone: 988128650

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Personal cancer risk testing using genetic, blood, and tumor monitoring

  This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07469709

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Colorectal Cancer Screening Outreach for Better Adherence

  This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.

  Recruiting Yale University · New Haven, Connecticut · NCT07345676

• Blood-based delta-HLD methylation test for detecting colorectal cancer

  This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.

  Recruiting Epiliquid Holding, Inc · Mendoza · NCT07148297

• MBRC-201 dose-finding and safety in advanced metastatic solid tumors

  We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.

  Recruiting at 7 sites Phase 1/2 MBrace Therapeutics · San Francisco, California and 6 other locations · NCT07145255

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.